Christopher Barbosa
Vice President, Technology Development
Dr. Christopher J. Barbosa is Vice President, Technology Development at Acuitas Therapeutics.
Chris obtained his BSc. (Hons) in Chemistry and a Ph.D. in Chemistry and Biotechnology from the University of British Columbia. He has held several leadership roles in the research and development of novel drug delivery systems, including Senior Scientist positions at INEX Pharmaceuticals and Angiotech Pharmaceuticals. While at INEX Pharmaceuticals, Chris contributed to the product development of several liposomal anticancer agents, including Marqibo™ (liposomal vincristine), Alocrest™ (liposomal vinorelbine), and Brakiva™ (liposomal topotecan). While at Angiotech Pharmaceuticals, Chris worked on the development of next-generation drug-eluting cardiovascular stents and other drug-eluting implantable medical device prototypes.
Chris is a key contributor to Acuitas’ rise to a global leadership position in the application of lipid nanoparticle technology for the delivery of nucleic acid therapeutics. He leads the internal development of lipids, scalable formulations, manufacturing processes and partnerships to facilitate Acuitas’ partners reaching the clinic and commercialization as safely, effectively and quickly as possible.